Phraxis

Executive Summary

Phraxis Inc. is a Minneapolis-based medical device company dedicated to improving hemodialysis access through its innovative EndoForce Connector. This minimally invasive implant enables an endovascular venous anastomosis for arteriovenous graft (AVG) implantation, potentially enhancing procedural outcomes and long-term graft patency. Led by an interventional nephrologist, the company targets the large and growing end-stage renal disease population requiring reliable vascular access for dialysis. Having achieved regulatory approval, Phraxis is now focused on commercializing the EndoForce Connector. The device addresses a critical unmet need in the hemodialysis access market, where traditional surgical techniques are invasive and have high failure rates. With a strong intellectual property portfolio and a clear value proposition, Phraxis is poised to capture significant market share. Success will depend on clinician adoption, reimbursement, and competitive dynamics.

Upcoming Catalysts (preview)

• Q3 2026US Commercial Launch of EndoForce Connector80% success
• Q1 2027Publication of Initial Clinical Outcomes70% success
• Q2 2027Strategic Partnership for Distribution60% success